生物活性分子抑制剂MI-773

生物活性分子抑制剂 特异性抑制剂 激动剂 化合物库 重组蛋白 MI-773  纯度: 98.05%

MI-773 是一种有效的 MDM2-p53 蛋白质相互作用 (PPI) 抑制剂,对 MDM2 具体高结合亲和力 (Kd=8.2 nM)。MI-773 具有抗肿瘤活性。

MI-773

MI-773 Chemical Structure

CAS No. : 1303607-07-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥1980 In-stock
5 mg ¥1600 In-stock
10 mg ¥2650 In-stock
50 mg ¥10600 In-stock
100 mg ¥17500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

MI-773 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Peptidomimetic Library
  • Anti-Aging Compound Library
  • Oxygen Sensing Compound Library
  • Ubiquitination Compound Library
  • Ferroptosis Compound Library
  • Pyroptosis Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

MI-773 is a potent MDM2-p53 protein‐protein interaction (PPI) inhibitor with high binding affinity against MDM2 (Kd=8.2 nM). MI-773 has antitumor activity[1][2].

体外研究
(In Vitro)

SAR405838 (MI-77301), an analog of MI-773, displays 10 times higher binding affinity against MDM2 than MI-773 (Kd=62 vs 8.2 nM). The antitumor activity of MI-77301 is more pronounced in a set of wild type p53 xenograft models than MI-773, including SJSA-1 osteosarcoma, human prostate, melanoma, colorectal tumor, LNCAP human prostate tumor and human acute lymphoblastic leukemia[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

562.50

Formula

C29H34Cl2FN3O3

CAS 号

1303607-07-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

溶解性数据
In Vitro: 

DMSO : ≥ 53 mg/mL (94.22 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7778 mL 8.8889 mL 17.7778 mL
5 mM 0.3556 mL 1.7778 mL 3.5556 mL
10 mM 0.1778 mL 0.8889 mL 1.7778 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.44 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.44 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (4.44 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.44 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Zhang Q, et al. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281-319.

    [2]. Tatyana A Grigoreva, et al. Amino acids as chiral derivatizing agents for antiproliferative substituted N-benzyl isoindolinones. Chirality. 2018 Jun;30(6):785-797.

Cell Assay

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Zhang Q, et al. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281-319.

    [2]. Tatyana A Grigoreva, et al. Amino acids as chiral derivatizing agents for antiproliferative substituted N-benzyl isoindolinones. Chirality. 2018 Jun;30(6):785-797.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务